Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUPH Aurinia Pharmaceuticals	$8.61 -0.2%	$8.16	$5.20 ▼ $10.67	$1.16B	1.16	1.40 million shs	207,130 shs
ELVN Enliven Therapeutics	$21.97 +0.4%	$20.16	$13.30 ▼ $30.03	$1.08B	0.83	306,126 shs	16,608 shs
GOSS Gossamer Bio	$1.72 -2.0%	$1.28	$0.66 ▼ $1.90	$392.09M	1.86	1.47 million shs	750,446 shs
NAGE Niagen Bioscience	$9.48 -2.1%	$12.03	$2.53 ▼ $14.69	$746.74M	2.14	897,468 shs	467,582 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUPH Aurinia Pharmaceuticals	-0.12%	-4.65%	+10.94%	+9.25%	+55.04%
ELVN Enliven Therapeutics	-3.49%	-4.91%	+2.68%	+21.70%	-0.64%
GOSS Gossamer Bio	+2.94%	+14.38%	+21.53%	+111.51%	+69.90%
NAGE Niagen Bioscience	-4.72%	-14.03%	-27.98%	+40.49%	+248.83%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUPH Aurinia Pharmaceuticals	3.2566 of 5 stars	3.5	2.0	0.0	3.6	0.8	1.9
ELVN Enliven Therapeutics	2.7141 of 5 stars	3.5	2.0	0.0	2.0	4.2	0.0
GOSS Gossamer Bio	3.5178 of 5 stars	3.5	1.0	4.7	1.1	1.7	0.0
NAGE Niagen Bioscience	1.6421 of 5 stars	3.5	0.0	0.0	3.0	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUPH Aurinia Pharmaceuticals	3.00	Buy	$11.50	33.64% Upside
ELVN Enliven Therapeutics	3.00	Buy	$41.20	87.57% Upside
GOSS Gossamer Bio	3.00	Buy	$8.25	381.05% Upside
NAGE Niagen Bioscience	3.00	Buy	$13.22	39.45% Upside

Current Analyst Ratings Breakdown

Latest GOSS, ELVN, NAGE, and AUPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/14/2025	GOSS Gossamer Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$11.00
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/10/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$13.00 ➝ $16.00
6/6/2025	NAGE Niagen Bioscience	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $23.00
5/27/2025	NAGE Niagen Bioscience	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$13.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/16/2025	GOSS Gossamer Bio	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $8.00
5/16/2025	GOSS Gossamer Bio	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$4.00 ➝ $4.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00

(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUPH Aurinia Pharmaceuticals	$235.13M	4.94	$0.31 per share	27.98	$2.68 per share	3.21
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
GOSS Gossamer Bio	$114.70M	3.40	N/A	N/A	$0.13 per share	13.19
NAGE Niagen Bioscience	$107.93M	6.92	$0.06 per share	171.85	$0.60 per share	15.80

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUPH Aurinia Pharmaceuticals	$5.75M	$0.28	30.77	15.37	N/A	16.11%	14.27%	9.93%	7/30/2025 (Estimated)
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
GOSS Gossamer Bio	-$56.53M	-$0.23	N/A	N/A	N/A	-41.12%	-128.98%	-15.52%	8/11/2025 (Estimated)
NAGE Niagen Bioscience	$8.55M	$0.17	55.76	∞	N/A	13.07%	19.06%	12.20%	N/A

Latest GOSS, ELVN, NAGE, and AUPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ELVN Enliven Therapeutics	-$0.54	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	GOSS Gossamer Bio	-$0.18	N/A	N/A	N/A	$4.12 million	N/A
8/7/2025	Q2 2025	AUPH Aurinia Pharmaceuticals	$0.18	N/A	N/A	N/A	$64.27 million	N/A
5/15/2025	Q1 2025	GOSS Gossamer Bio	-$0.18	-$0.16	+$0.02	-$0.16	$3.95 million	$9.89 million
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	AUPH Aurinia Pharmaceuticals	$0.08	$0.16	+$0.08	$0.16	$61.06 million	$62.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUPH Aurinia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
NAGE Niagen Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUPH Aurinia Pharmaceuticals	0.16	5.93	5.26
ELVN Enliven Therapeutics	N/A	21.07	21.06
GOSS Gossamer Bio	6.70	5.71	5.71
NAGE Niagen Bioscience	N/A	3.66	3.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUPH Aurinia Pharmaceuticals	36.83%
ELVN Enliven Therapeutics	95.08%
GOSS Gossamer Bio	81.23%
NAGE Niagen Bioscience	15.41%

Insider Ownership

Company	Insider Ownership
AUPH Aurinia Pharmaceuticals	12.20%
ELVN Enliven Therapeutics	25.90%
GOSS Gossamer Bio	6.70%
NAGE Niagen Bioscience	9.39%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUPH Aurinia Pharmaceuticals	300	135.10 million	118.62 million	Optionable
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
GOSS Gossamer Bio	180	227.30 million	212.07 million	Optionable
NAGE Niagen Bioscience	120	78.77 million	71.37 million	N/A

GOSS, ELVN, NAGE, and AUPH Headlines

Recent News About These Companies

Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives $13.22 Average PT from Analysts

July 19 at 2:59 AM | americanbankingnews.com

Niagen Bioscience (NASDAQ:NAGE) Shares Down 4% - Here's What Happened

July 18, 2025 | marketbeat.com

Niagen Bioscience Inc. (NAGE) Stock Price Today - WSJ

July 18, 2025 | wsj.com

Robert Fried Says Niagen Bioscience Has the Key to Better Aging, and He Has the Science to Prove It

July 16, 2025 | latimes.com

Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Consensus Recommendation of "Buy" from Analysts

July 14, 2025 | marketbeat.com

Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York

July 14, 2025 | theglobeandmail.com

Niagen Bioscience Announces the Debut of Tru NiagenÂ® and Niagen IV at Equinox Hotel New York

July 14, 2025 | businesswire.com

Niagen Bioscience stock rises on exclusive Parkinson’s treatment license

July 9, 2025 | in.investing.com

Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy

July 9, 2025 | msn.com

Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson's Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway

July 8, 2025 | businesswire.com

NAGE - Niagen Bioscience Inc Executives - Morningstar

July 1, 2025 | morningstar.comM

Niagen Bioscience (NASDAQ:NAGE) Stock Price Down 9.5% - Here's What Happened

July 1, 2025 | marketbeat.com

Earnings Forecast & History for Niagen Bioscience Inc (NAGE) | Price Reactions

July 1, 2025 | investing.com

Niagen Bioscience (NASDAQ:NAGE) Reaches New 1-Year High - What's Next?

June 30, 2025 | marketbeat.com

2NAGE : Breaking Update: Wendy Tak Wing YU Engages In Options Exercise At Niagen...

June 27, 2025 | benzinga.com

1NAGE : Engaging In Insider Activity, Kristin Patrick At Niagen Bioscience Exercises...

June 27, 2025 | benzinga.com

Major Update: Frank Jaksch Jr At Niagen Bioscience Exercises Options, Realizing $0

June 26, 2025 | benzinga.com

Options Exercise Update At Niagen Bioscience: Ann Cohen Engages, Resulting In $0

June 26, 2025 | benzinga.com

Steven Rubin At Niagen Bioscience Exercises Options Worth $0

June 26, 2025 | benzinga.com

Niagen Bioscience, Inc. (NAGE) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

Niagen Biosciences: Anti-Aging Market Leader And Prime Beneficiary Of Long-Term Demographic Trends

June 24, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
By Gabriel Osorio-Mazilli | June 25, 2025
View ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside
Tesla: 2 Plays Ahead of Next Week's Earnings Report
By Sam Quirke | July 15, 2025
View Tesla: 2 Plays Ahead of Next Week's Earnings Report
This Fund Manager Says You Should Get Out of Tesla and Apple—Now
By Brian O'Connell | July 16, 2025
View This Fund Manager Says You Should Get Out of Tesla and Apple—Now
Full Steam Ahead: The Bullish Case for Carnival Stock
By Jeffrey Neal Johnson | July 18, 2025
View Full Steam Ahead: The Bullish Case for Carnival Stock
Will Dollar Tree Break Out After a New $2.5 Billion Buyback?
By Gabriel Osorio-Mazilli | July 15, 2025
View Will Dollar Tree Break Out After a New $2.5 Billion Buyback?

GOSS, ELVN, NAGE, and AUPH Company Descriptions

Aurinia Pharmaceuticals NASDAQ:AUPH

$8.60 -0.02 (-0.17%)

As of 11:22 AM Eastern

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Enliven Therapeutics NASDAQ:ELVN

$21.96 +0.10 (+0.43%)

As of 11:22 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Gossamer Bio NASDAQ:GOSS

$1.72 -0.04 (-2.00%)

As of 11:22 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Niagen Bioscience NASDAQ:NAGE

$9.48 -0.20 (-2.07%)

As of 10:52 AM Eastern

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time